Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 16 results.
User Information
Export Records
  1. 1.   Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma
  2. Reid, Erin G; Suazo, Adrienne; Lensing, Shelly Y; Dittmer, Dirk P; Ambinder, Richard F; Maldarelli, Frank; Gorelick,Robert; Aboulafia, David M; Mitsuyasu, Ronald; Dickson, Mark A; Wachsman, William
  3. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020, FEB; 26(3): 558-565.
  1. 2.   Targeting the extrinsic apoptosis signaling pathway for cancer therapy
  2. Sayers, T. J.
  3. Cancer Immunology Immunotherapy. 2011, Aug; 60(8): 1173-1180.
  1. 3.   Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
  2. Lee, S.; Yagita, H.; Sayers, T. J.; Celis, E.
  3. Cancer Immunology Immunotherapy. 2010, Jul; 59(7): 1073-1081.
  1. 4.   Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL-Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways
  2. Seki, N.; Toh, U.; Sayers, T. J.; Fujii, T.; Miyagi, M.; Akagi, Y.; Kusukawa, J.; Kage, M.; Shirouzu, K.; Yamana, H.
  3. Molecular Cancer Therapeutics. 2010, Jun; 9(6): 1842-1851.
  1. 5.   Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex
  2. Brooks, A. D.; Jacobsen, K. M.; Li, W. Q.; Shanker, A.; Sayers, T. J.
  3. Molecular Cancer Research. 2010, May; 8(5): 729-738.
  1. 6.   Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition
  2. Hallett, W.; Ames, E.; Motarjemi, M.; Barao, I.; Shanker, A.; Tamang, D. L.; Sayers, T. J.; Hudig, D.; Murphy, W. J.
  3. Journal of Immunology. 2008 180(1): 163-170.
  1. 7.   Productively combining proteasome inhibition with the immunotherapy of cancer
  2. Sayers, T.
  3. Journal of Molecular Medicine-jmm. 2008 86(8): 857-860.
  1. 8.   Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
  2. Shanker, A.; Brooks, A. D.; Tristan, C. A.; Wine, J. W.; Elliott, P. J.; Yagita, H.; Takeda, K.; Smyth, M. J.; Murphy, W. J.; Sayers, T. J.
  3. Journal of the National Cancer Institute. 2008 100(9): 649-662.
  1. 9.   Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics
  2. Yang, Y. L.; Kitagaki, J.; Dai, R. M.; Tsai, Y. C.; Lorick, K. L.; Ludwig, R. L.; Pierre, S. A.; Jensen, J. P.; Davydov, I. V.; Oberoi, P.; Li, C. C. H.; Kenten, J. H.; Beutler, J. A.; Vousden, K. H.; Weissman, A. M.
  3. Cancer Research. 2007, Oct; 67(19): 9472-9481.
  1. 10.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 11.   TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
  2. Cretney, E.; Shanker, A.; Yagita, H.; Smyth, M. J.; Sayers, T. J.
  3. Immunology and Cell Biology. 2006, FEB; 84(1): 87-98.
  1. 12.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 13.   Structure-based discovery of a boronic acid bioisostere of combretastatin A-4
  2. Kong, Y.; Grembecka, J.; Edler, M. C.; Hamel, E.; Mooberry, S. L.; Sabat, M.; Rieger, J.; Brown, M. L.
  3. Chemistry & Biology. 2005, SEP; 12(9): 1007-1014.
  1. 14.   The proteasome inhibitor bortezomib sensitizes human tumor cells to TRAIL-mediated apoptosis
  2. Sayers, T. J.; Brooks, A. D.; Ramirez, T.; Elliott, P. J.; Murphy, W. J.
  3. Journal of Immunotherapy. 2005, NOV-DEC; 28(6): 641-641.
  1. 15.   Tumor therapy with proteasome inhibitor bortezomib (Velcade, PS-341) plus death receptor (DR5) agonist antibody MD5.1
  2. Shanker, A.; Brooks, A. D.; Tristan, C. A.; Sayers, T. J.
  3. Journal of Immunotherapy. 2005, NOV-DEC; 28(6): 641-641.
  1. 16.   The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis
  2. Brooks, A. D.; Ramirez, T.; Toh, U.; Onksen, J.; Elliott, P. J.; Murphy, W. J.; Sayers, T. J.
  3. Tumor Progression and Therapeutic Resistance. 2005; 1059 : 160-167.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel